Samin Sadraei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Samin Sadraei has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Aryan Aarabi
Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran
4 shared publications - Ida Mohammadi
School of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran
3 shared publications - Shahryar Rajai Firouzabadi
School of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran
3 shared publications - Arman Shafiee
Alborz University of Medical Sciences
2 shared publications - Masoumeh Rajabibazl
Department of Clinical Biochemistry, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 shared publications Aidin Saadati
School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- 17 July 2026
- Published by Springer Nature in European Spine Journal
- p. 1-17
Prevalence and risk factors of sleep disturbances before and after spinal surgeries: a systematic review and meta-analysis
Background Sleep disturbances frequently affect patients undergoing spinal surgery, impairing recovery, reducing quality of life, increasing postoperative complications, and impairing physical function improvements. However, the prevalence and associated risk factors of these disturbances remain poorly understood. This systematic review and meta-analysis aims to bridge this gap. Methods The review protocol was prospectively registered on PROSPERO (CRD42024599851). A comprehensive search of PubMed, Embase, Cochrane Library, and Web of Science was conducted on November 14th, 2025. Studies evaluating sleep disturbances in adults undergoing spinal surgery were included. Proportional meta-analysis was conducted using a generalized linear mixed model. Studies utilizing sleep questionnaires and studies using spinal disability outcome measures with a sleep component were meta-analyzed separately. Heterogeneity was investigated via meta-regressions. Risk of bias was assessed using the Newcastle-Ottawa scale (NOS). Results Twenty studies were included. Preoperative sleep disturbance prevalence varied substantially by assessment instrument, ranging from 44.7% (95% CI: 28.6% to 61.7%) using PIRS-20 and 54.3% (95% CI: 47.7% to 60.8%) using PROMIS-SD to 91.2% (95% CI: 70.5% to 97.8%) using the PSQI. Younger age explained part of the between-study heterogeneity. Postoperative sleep disturbance prevalence was 35.3% (95% CI: 14.3% to 64.0%) using the PSQI and 29.7% (95% CI: 24.4% to 35.6%) using PROMIS-SD, while male sex was associated with a higher postoperative prevalence. Spinal disability outcome measures reported preoperative and postoperative sleep disturbance prevalences ranging from 79.7% to 84.2% and 27.2% to 52.0%, respectively. Consistent preoperative risk factors included younger age, female sex, greater pain severity, disability, and lower educational attainment. Greater pain, pre-existing sleep problems, and increased intraoperative bleeding volume were the most consistent postoperative risk factors. Conclusions Sleep disturbances are highly prevalent before spinal surgery and remain common after surgery, although prevalence estimates vary substantially according to the assessment instrument used. Pain and disability appear to be important determinants of perioperative sleep disturbance. Routine screening and targeted perioperative interventions may improve patient outcomes.
- 17 July 2026
- Published by Springer Nature in European Spine Journal
- p. 1-17
Prevalence and risk factors of sleep disturbances before and after spinal surgeries: a systematic review and meta-analysis
Background Sleep disturbances frequently affect patients undergoing spinal surgery, impairing recovery, reducing quality of life, increasing postoperative complications, and impairing physical function improvements. However, the prevalence and associated risk factors of these disturbances remain poorly understood. This systematic review and meta-analysis aims to bridge this gap. Methods The review protocol was prospectively registered on PROSPERO (CRD42024599851). A comprehensive search of PubMed, Embase, Cochrane Library, and Web of Science was conducted on November 14th, 2025. Studies evaluating sleep disturbances in adults undergoing spinal surgery were included. Proportional meta-analysis was conducted using a generalized linear mixed model. Studies utilizing sleep questionnaires and studies using spinal disability outcome measures with a sleep component were meta-analyzed separately. Heterogeneity was investigated via meta-regressions. Risk of bias was assessed using the Newcastle-Ottawa scale (NOS). Results Twenty studies were included. Preoperative sleep disturbance prevalence varied substantially by assessment instrument, ranging from 44.7% (95% CI: 28.6% to 61.7%) using PIRS-20 and 54.3% (95% CI: 47.7% to 60.8%) using PROMIS-SD to 91.2% (95% CI: 70.5% to 97.8%) using the PSQI. Younger age explained part of the between-study heterogeneity. Postoperative sleep disturbance prevalence was 35.3% (95% CI: 14.3% to 64.0%) using the PSQI and 29.7% (95% CI: 24.4% to 35.6%) using PROMIS-SD, while male sex was associated with a higher postoperative prevalence. Spinal disability outcome measures reported preoperative and postoperative sleep disturbance prevalences ranging from 79.7% to 84.2% and 27.2% to 52.0%, respectively. Consistent preoperative risk factors included younger age, female sex, greater pain severity, disability, and lower educational attainment. Greater pain, pre-existing sleep problems, and increased intraoperative bleeding volume were the most consistent postoperative risk factors. Conclusions Sleep disturbances are highly prevalent before spinal surgery and remain common after surgery, although prevalence estimates vary substantially according to the assessment instrument used. Pain and disability appear to be important determinants of perioperative sleep disturbance. Routine screening and targeted perioperative interventions may improve patient outcomes.
- Open Access
- 13 December 2025
- Published by Taylor & Francis in Critical Public Health
- Vol. 36 (1)
The association between consumption of a mediterranean diet and shortness of breath in older adults: a cross-sectional NHANES analysis
- 13 December 2025
- Published by Taylor & Francis in Critical Public Health
- Vol. 36 (1)
Open AccessThe association between consumption of a mediterranean diet and shortness of breath in older adults: a cross-sectional NHANES analysis
- 3 April 2025
- Published by Springer Nature in neurogenetics
- Vol. 26 (1) , 1-19
The association of SCN1A polymorphisms with epilepsy and drug resistance: a systematic review and meta-analysis
Epilepsy is one of the most common neurological afflictions worldwide, with one-third of patients exhibiting resistance to treatment. It has been speculated that the polymorphisms of the sodium channel alpha subunit 1 (SCN1A) gene are associated with both the occurrence of epilepsy and its resistance to treatment. The aim of this study is to systematically review the literature and conduct meta-analyses revealing the associations of the SCN1A polymorphisms with epilepsy and resistance to treatment. We conducted a search of Pubmed, Web of Science, and Scopus, and if more than two studies investigated a polymorphism, odds ratios for association with epilepsy and/or resistance to treatment were calculated in three allelic, homozygous, and recessive genetic models. The initial search yielded 4106 items, and a total of 64 articles met the final inclusion criteria. With respect to the occurrence of epilepsy, the rs2298771 polymorphism was revealed to be negatively associated in the recessive model, while the associations of other polymorphisms were not statistically significant. With regard to resistance to treatment, rs2298771 was revealed to be positively associated across all three models, and rs10167228 was positively associated in the allelic and homozygous models, but not the recessive model. Other polymorphisms were not shown to be associated with resistance to treatment. In conclusion, we demonstrated that the rs2298771 polymorphism had a significant and negative association with the occurrence of epilepsy. Furthermore, rs2298771 and rs10167228 polymorphisms had positive associations with resistance to treatment. Further studies are needed to explore these associations among other polymorphisms.
- 3 April 2025
- Published by Springer Nature in neurogenetics
- Vol. 26 (1) , 1-19
The association of SCN1A polymorphisms with epilepsy and drug resistance: a systematic review and meta-analysis
Epilepsy is one of the most common neurological afflictions worldwide, with one-third of patients exhibiting resistance to treatment. It has been speculated that the polymorphisms of the sodium channel alpha subunit 1 (SCN1A) gene are associated with both the occurrence of epilepsy and its resistance to treatment. The aim of this study is to systematically review the literature and conduct meta-analyses revealing the associations of the SCN1A polymorphisms with epilepsy and resistance to treatment. We conducted a search of Pubmed, Web of Science, and Scopus, and if more than two studies investigated a polymorphism, odds ratios for association with epilepsy and/or resistance to treatment were calculated in three allelic, homozygous, and recessive genetic models. The initial search yielded 4106 items, and a total of 64 articles met the final inclusion criteria. With respect to the occurrence of epilepsy, the rs2298771 polymorphism was revealed to be negatively associated in the recessive model, while the associations of other polymorphisms were not statistically significant. With regard to resistance to treatment, rs2298771 was revealed to be positively associated across all three models, and rs10167228 was positively associated in the allelic and homozygous models, but not the recessive model. Other polymorphisms were not shown to be associated with resistance to treatment. In conclusion, we demonstrated that the rs2298771 polymorphism had a significant and negative association with the occurrence of epilepsy. Furthermore, rs2298771 and rs10167228 polymorphisms had positive associations with resistance to treatment. Further studies are needed to explore these associations among other polymorphisms.
- 23 March 2024
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-10
STAT protein family and cardiovascular diseases: overview of pathological mechanisms and therapeutic implications
Globally, cardiovascular diseases (CVD) are one of the significant causes of death and are considered a major concern of human society. One of the most crucial objectives of scientists is to reveal the mechanisms associated with the pathogenesis of CVD, which has attracted the attention of many scientists. Accumulating evidence showed that the signal transducer and activator of transcription (STAT) signaling pathway is involved in various physiological and pathological processes. According to research on the molecular mechanisms of CVDs, the STAT family of proteins is one of the most crucial players in these diseases. Numerous studies have demonstrated the undeniable relevance of STAT family proteins in various CVDs. The aim of this review is to shed light on how STAT signaling pathways are related to CVD and the potential for using these signaling pathways as therapeutic targets.
- 23 March 2024
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-10
STAT protein family and cardiovascular diseases: overview of pathological mechanisms and therapeutic implications
Globally, cardiovascular diseases (CVD) are one of the significant causes of death and are considered a major concern of human society. One of the most crucial objectives of scientists is to reveal the mechanisms associated with the pathogenesis of CVD, which has attracted the attention of many scientists. Accumulating evidence showed that the signal transducer and activator of transcription (STAT) signaling pathway is involved in various physiological and pathological processes. According to research on the molecular mechanisms of CVDs, the STAT family of proteins is one of the most crucial players in these diseases. Numerous studies have demonstrated the undeniable relevance of STAT family proteins in various CVDs. The aim of this review is to shed light on how STAT signaling pathways are related to CVD and the potential for using these signaling pathways as therapeutic targets.
- Open Access
- 13 May 2022
- Published by Springer Nature in Cellular & Molecular Biology Letters
- Vol. 27 (1) , 1-56
An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19)
Designing and producing an effective vaccine is the best possible way to reduce the burden and spread of a disease. During the coronavirus disease 2019 (COVID-19) pandemic, many large pharmaceutical and biotechnology companies invested a great deal of time and money in trying to control and combat the disease. In this regard, due to the urgent need, many vaccines are now available earlier than scheduled. Based on their manufacturing technology, the vaccines available for COVID-19 (severe acute respiratory syndrome coronavirus 2 (SAR-CoV2)) infection can be classified into four platforms: RNA vaccines, adenovirus vector vaccines, subunit (protein-based) vaccines, and inactivated virus vaccines. Moreover, various drugs have been deemed to negatively affect the progression of the infection via various actions. However, adaptive variants of the SARS-CoV-2 genome can alter the pathogenic potential of the virus and increase the difficulty of both drug and vaccine development. In this review, along with drugs used in COVID-19 treatment, currently authorized COVID-19 vaccines as well as variants of the virus are described and evaluated, considering all platforms.Graphical abstract
- 13 May 2022
- Published by Springer Nature in Cellular & Molecular Biology Letters
- Vol. 27 (1) , 1-56
Open AccessAn overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19)
Designing and producing an effective vaccine is the best possible way to reduce the burden and spread of a disease. During the coronavirus disease 2019 (COVID-19) pandemic, many large pharmaceutical and biotechnology companies invested a great deal of time and money in trying to control and combat the disease. In this regard, due to the urgent need, many vaccines are now available earlier than scheduled. Based on their manufacturing technology, the vaccines available for COVID-19 (severe acute respiratory syndrome coronavirus 2 (SAR-CoV2)) infection can be classified into four platforms: RNA vaccines, adenovirus vector vaccines, subunit (protein-based) vaccines, and inactivated virus vaccines. Moreover, various drugs have been deemed to negatively affect the progression of the infection via various actions. However, adaptive variants of the SARS-CoV-2 genome can alter the pathogenic potential of the virus and increase the difficulty of both drug and vaccine development. In this review, along with drugs used in COVID-19 treatment, currently authorized COVID-19 vaccines as well as variants of the virus are described and evaluated, considering all platforms.Graphical abstract